API-1 是一种有效的选择性 Akt/PKB 抑制剂,可通过结合 PH 结构域并抑制 Akt 膜易位来降低磷酸化 Akt 水平 (IC50 = 0.8 μM),诱导 c-FLIP 降解,降低细胞增殖并诱导细胞凋亡 (apoptosis),同时可降低小鼠异种移植模型中的肿瘤生长。
产品编号: MS-G08574 纯度: 99.62% CAS No.: 36707-00-3 分子式: C13H15N5O6 分子量: 337.29
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价

产品描述

API-1 是一种有效的选择性 Akt/PKB 抑制剂,可通过结合 PH 结构域并抑制 Akt 膜易位来降低磷酸化 Akt 水平 (IC50 = 0.8 μM),诱导 c-FLIP 降解,降低细胞增殖并诱导细胞凋亡 (apoptosis),同时可降低小鼠异种移植模型中的肿瘤生长。

生物实验数据

生物活性 API-1 is a potent and selective Akt/PKB inhibitor that reduces phosphorylated Akt levels (IC50 = 0.8 μM) by binding to the PH domain and inhibiting Akt membrane translocation, induces c-FLIP degradation, decreases cell proliferation and induces apoptosis, and reduces tumor growth in mouse xenograft models.
IC50 & Target

Caspase-8

 

Caspase 3

 

Caspase-9

 

PARP

 

体外研究
(In Vitro)

API-1 (0.625-10 μM,3 天) 可有效抑制非小细胞肺癌 (NSCLC) 和头颈部鳞状细胞癌 (HNSCC) 细胞系的生长。
API-1 (5-10 μM,24 小时) 可有效诱导 API-1 敏感的 NSCLC 和 HNSCC 细胞系凋亡。
API-1 (1.25-5 μM,24 小时) 可与凋亡诱导配体 (TRAIL) 协同诱导 H1229 和 22A 细胞凋。
API-1 (0.625-10 μM,2-24 小时) 降低 NSCLC 和 HNSCC 细胞中c-FLIP 水平 (通过促进泛素/蛋白酶体介导的降解),而不会增加 DR4 或 DR5 的表达。
API-1 (0.625-10 μM, 2-24 小时) 可抑制 NSCLC 和 HNSCC 细胞中 Akt 的磷酸化。
API-1 (0.5-20 μM,12-72 小时) 诱导 GSK3 依赖性、β-TrCP 和 FBXW7 介导的 Mcl-1 降解,从而诱导 NSCLC 细胞系凋亡。

Cell Proliferation Assay

Cell Line: Human non-small cell lung cancer (NSCLC) cell lines (H157, Calu-1 and H1299) and head and neck squamous cell carcinoma (HNSCC) cell lines (22A, Tr146 and SqCC/Y1)
Concentration: 0.625, 1.25, 2.5, 5, 10 μM
Incubation Time: 3 d
Result: Effectively inhibited the growth of 5 (H1299, H157, SqCC/Y1, 22A and Tr146) of 6 tested cancer cell lines.
The effective concentrations that decreased cell numbers by 50% (IC50s) ranged between 2 and 5 μM for these sensitive cell lines.

Apoptosis Analysis

Cell Line: H1299, Calu-1, SqCC/Y1
Concentration: 5, 10 μM
Incubation Time: 24 h
Result: Dose-dependently increased annexin V-positive (or apoptotic) cells in H1299 and SqCC/Y1 cells (> 40% at 10 μM), but did so only minimally in Calu-1 cells (< 15% at 10 μM).
Dose-dependent increased cleavage of caspase-8, caspase-9, caspase-3 and PARP in H1299 and SqCC/Y1 cells, but this was not apparent in Calu-1 cells.

Apoptosis Analysis

Cell Line: H1299, H157, Calu-1, SqCC/Y1, 22A, Tr146
Concentration: 1,25, 2.5, 5 μM; 5 μM (H1299, 22A)
Incubation Time: 24 h
Result: Combination (5 or 2.5 μM) with TRAIL (25 to 100 ng/ml) was much more effective than either agent alone in decreasing the survival of the tested NSCLC and HNSCC cell lines, except for Calu-1 cells.
The CIs for these combinations were < 1.
Combination with TRAIL was much more potent than used alone in increasing cleavage of caspase-8, caspase-9, caspase-3 and PARP in H1229 and 22A.
Increased the proportion of annexin Vpositive cells in H1229 and 22A.

Western Blot Analysis

Cell Line: H1299, H157, Calu-1, SqCC/Y1, 22A, Tr146
Concentration: 5 μM; 0.625, 1.25, 2.5, 5, 10 μM (H157)
Incubation Time: 24 h; 12 h (H157 with different concentrations); 2, 4, 8, 12, 16 h (H157 with concentration of 5 μM)
Result: Reduced the levels of c-FLIP in H157, H1299, SqCC/Y1 and Tr146 cells, but not in Calu-1 cells at 5 μM.
Did not increase the expression of either DR5 or DR4 in any of the cell lines.
Reduced the levels of DR4 in some cell lines (H1299, SqCC/Y1 and Tr146).
Showed dose-course and time-course studies of the effects on the levels of c-FLIP, DR4 and DR5 in H157 cells.
The apparent reduction of c-FLIP in cells occurred after 4 h exposure.
体内研究
(In Vivo)

API-1 (10 mg/kg;腹腔注射;每天一次,持续 6-8 周) 在 OVCAR3 和 PANC-1 异种移植小鼠肿瘤模型中选择性地抑制 Akt 过度活化的肿瘤的生长。

Animal Model: 8-week-old female nude mice (implanted tumors with hyperactivated Akt (OVCAR3 and PANC-1) into the left flank and those tumors that express low levels of activated Akt (OVCAR5 and COLO357) into the right flank)
Dosage: 10 mg/kg
Administration: Intraperitoneal injection (i.p.); daily for 6-8 weeks
Result: Inhibited OVCAR3 and PANC1 tumor growth by 70 and 50%, respectively.
Had little effect on the growth of OVCAR5 and COLO357 cells in nude mice.
Had no effects on blood glucose level, body weight, activity, and food intake of mice.
Phosphorylation levels of Akt were reduced about 70% without a change of total Akt content.
性状 固体
颜色 White to off-white

化学信息

分子量 337.29
分子式 C13H15N5O6
CAS No. 36707-00-3

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.93 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (148.24 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.9648 mL14.8240 mL29.6481 mL74.1202 mL
5 mM0.5930 mL2.9648 mL5.9296 mL14.8240 mL
10 mM0.2965 mL1.4824 mL2.9648 mL7.4120 mL
15 mM0.1977 mL0.9883 mL1.9765 mL4.9413 mL
20 mM0.1482 mL0.7412 mL1.4824 mL3.7060 mL
25 mM0.1186 mL0.5930 mL1.1859 mL2.9648 mL
30 mM0.0988 mL0.4941 mL0.9883 mL2.4707 mL
40 mM0.0741 mL0.3706 mL0.7412 mL1.8530 mL
50 mM0.0593 mL0.2965 mL0.5930 mL1.4824 mL
60 mM0.0494 mL0.2471 mL0.4941 mL1.2353 mL
80 mM0.0371 mL0.1853 mL0.3706 mL0.9265 mL
100 mM0.0296 mL0.1482 mL0.2965 mL0.7412 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础